[go: up one dir, main page]

PE20040797A1 - Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion - Google Patents

Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion

Info

Publication number
PE20040797A1
PE20040797A1 PE2003001178A PE2003001178A PE20040797A1 PE 20040797 A1 PE20040797 A1 PE 20040797A1 PE 2003001178 A PE2003001178 A PE 2003001178A PE 2003001178 A PE2003001178 A PE 2003001178A PE 20040797 A1 PE20040797 A1 PE 20040797A1
Authority
PE
Peru
Prior art keywords
growth hormone
human growth
sticked
preparation
terminal
Prior art date
Application number
PE2003001178A
Other languages
English (en)
Inventor
Rory F Finn
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of PE20040797A1 publication Critical patent/PE20040797A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN CONJUGADO DE HORMONA DE CRECIMIENTO HUMANA-PEG DE FORMULAS I o II, EN LA QUE n Y m SON, INDEPENDIENTEMENTE ENTRE SI, UN NUMERO ENTERO ENTRE 1 A 10; R ES UNA HORMONA DE CRECIMIENTO HUMANA u HORMONA DE CRECIMIENTO HUMANA METIONILO; EN DONDE DICHA HORMONA DE CRECIMIENTO HUMANA COMPRENDE UNA SECUENCIA AMINOACIDICA DE SEC Nº ID 1 Y QUE SE CONJUGA CON EL POLIETILENGLICOL (PEG) A TRAVES DE UNA FENILALANINA AMINOTERMINAL Y EN LA QUE CADA PEG TIENE UN PESO APROXIMADO DE 20 Kda. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE DICHO CONJUGADO Y AL MENOS UN VEHICULO FARMACEUTICAMENTE ACEPTABLE Y QUE ES UTIL PARA EL TRATAMIENTO DE TRASTORNOS DE CRECIMIENTO O DESARROLLO DEBIDO A UNA DEFICIENCIA DE HORMONA DE CRECIMIENTO (DHC), SINDROME DE TURNER, INSUFICIENCIA CRONICA RENAL
PE2003001178A 2002-11-20 2003-11-20 Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion PE20040797A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42782302P 2002-11-20 2002-11-20

Publications (1)

Publication Number Publication Date
PE20040797A1 true PE20040797A1 (es) 2004-12-10

Family

ID=32825103

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001178A PE20040797A1 (es) 2002-11-20 2003-11-20 Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion

Country Status (9)

Country Link
US (1) US20040127417A1 (es)
AR (1) AR042103A1 (es)
GT (1) GT200300250A (es)
NL (3) NL1024831C2 (es)
PA (1) PA8588901A1 (es)
PE (1) PE20040797A1 (es)
SV (1) SV2004001674A (es)
TW (1) TWI281864B (es)
UY (1) UY28085A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
EA200500475A1 (ru) 2002-09-09 2005-10-27 Нектар Терапеутикс Ал, Корпорейшн Водорастворимые полимерные алканалы
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
CN102319437B (zh) * 2002-12-26 2017-10-13 山景医药公司 具有增强的生物学效用的干扰素‑β的聚合物缀合物
JP2006519170A (ja) * 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
BRPI0507436A (pt) * 2004-02-09 2007-07-03 Pharmacia Corp conjugados antagonistas de receptor do hormÈnio do crescimento humano quimicamente modificados
WO2006042847A2 (en) * 2004-10-18 2006-04-27 Novo Nordisk A/S Method for the preparation of oxime, thiazolidine, dithiane, dithiolane or hydrazone linked analogues of growth hormone
WO2006042848A2 (en) * 2004-10-18 2006-04-27 Novo Nordisk A/S Growth hormone conjugates
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
CA2620638A1 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
WO2007097934A2 (en) * 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs
US9175061B2 (en) * 2006-07-07 2015-11-03 Novo Nordisk Health Care Ag Protein conjugates and methods for their preparation
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
EP2157432A1 (en) * 2008-08-15 2010-02-24 Qiagen GmbH Method for analysing a complex sample by mass spectrometry
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP3355384A1 (en) * 2017-01-31 2018-08-01 Universite De Liege Flexible thin-films for battery electrodes
CN114539384B (zh) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5618697A (en) * 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DE68925966T2 (de) * 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
CA2230492C (en) * 1995-09-21 2009-05-26 Genentech, Inc. Human growth hormone variants
KR100731826B1 (ko) * 1999-01-14 2007-06-22 볼더 바이오테크놀로지 인코퍼레이티드 유리 시스테인 잔기를 함유하는 단백질의 제조 방법
SE9904502D0 (sv) * 1999-12-09 1999-12-09 Pharmacia & Upjohn Ab Production of peptides

Also Published As

Publication number Publication date
PA8588901A1 (es) 2005-02-04
NL1024831C2 (nl) 2005-04-28
NL1032282C2 (nl) 2007-03-09
GT200300250A (es) 2004-08-18
NL1028837A1 (nl) 2005-08-30
TWI281864B (en) 2007-06-01
UY28085A1 (es) 2004-07-30
SV2004001674A (es) 2004-05-17
NL1024831A1 (nl) 2004-05-26
NL1028837C2 (nl) 2006-08-14
TW200418878A (en) 2004-10-01
AR042103A1 (es) 2005-06-08
NL1032282A1 (nl) 2006-11-07
US20040127417A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
PE20040797A1 (es) Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion
BR9815159A (pt) Preparação de conjugados de polietileno glicol-grf especìfica ao sìtio
LU92237I2 (fr) Pegloticase et toute forme thérapeutique équivalente protégée par le brevet de base
AR008378A1 (es) Conjudados de interferon
WO2021115497A3 (zh) 蛋白-药物偶联物和定点偶联方法
DE60235010D1 (de) Monodisperse gemische aus calcitonin-arzneimittel-oligomer-konjugaten mit polyethylenglycol, ihre verwendung und verfahren zu ihrer herstellung
AR047062A1 (es) Conjugados portadores de peptidos inmunogenicos a beta y metodos para producirlos
NO20074267L (no) Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid
DK0966297T4 (da) Regulering af gastrointestinal motilitet
BRPI0417341A (pt) fator ix glicopeguilado
CY1117358T1 (el) ΔΙΑΛΥΤΗ ΓΛΥΚΟΠΡΩΤΕΪΝΗ ΥΑΛΟΥΡΟΝΙΔΑΣΗΣ (sHASEGP), ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΗΣ, ΧΡΗΣΕΙΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΛΑΜΒΑΝΟΥΝ
BRPI0417744A (pt) métodos para conjugar um imunogene de peptìdeo e para induzir uma resposta imune em um indivìduo mamìfero, conjugado de portador de peptìdeo de imunogene-proteìna/polipeptìdeo e composição imunogênica
MX9700552A (es) Conjugados de vitamina b12 y proteinas.
BR0012200B1 (pt) composição de peptídeo para o tratamento de disfunção sexual e composição farmacêutica para o tratamento de disfunção sexual em um mamífero.
DK199901377A (da) Rekombinant pseudomonas exotoxin og opbygning af aktivt immunotoxin
DE3786000D1 (de) Conjugate dichter sterne.
IL135148A0 (en) A polysaccharide conjugate and pharmaceutical compositions containing the same
DE60043620D1 (de) Mage-a1 peptide die von klasse ii hla molekule presentiert werden
NO975547L (no) Vaksiner med modifiserte meningokokk/polysakkarid-konjugater
EP1242115A4 (en) CHEMICALLY PROGRAMMABLE IMMUNITY
ES2180279T3 (es) Compuesto de hierro-dextrano para utilizacion como componente en composicion terapeutica para profilaxis o tratamiento de deficiencia de hierro, procedimiento para su produccion y utilizacion del mismo para preparacion de composicion terapeutica administrable por via parenteral.
DE69231663D1 (de) Konjugate bestehend aus polysaccharid und protein
WO1995011977A3 (en) A NEW RIBOSOME-INACTIVATING PROTEIN ISOLATED FROM THE PLANT $i(BRYONIA DIOICA)
EP0698040A1 (en) Lhrh antagonists
CO5570658A2 (es) Composicion y metodo para el tratamiento de la diabetes

Legal Events

Date Code Title Description
FC Refusal